BioNTech extends COVID-19 vaccine trial in China to end-Oct – ET HealthWorld

Beijing: Vaccine developer BioNTech has extended by six months to October a Phase II clinical trial of its COVID-19 vaccine in China, a registry of such trials showed. The vaccine, based on messenger RNA (mRNA) technology, is one of the most widely used worldwide against COVID, but has yet to receive an approval in China, which has relied only on domestically developed vaccine. China’s leading medical experts have urged authorities to retain tough zero-COVID measures so as to buy time and step up vaccination rates and develop new treatments, in…

Read More

NIH assesses third COVID-19 vaccine dose in kidney transplant recipients – ET HealthWorld

By Manojna Maddipatla The U.S. National Institutes of Health (NIH) said on Tuesday it had launched a new study to assess how patients on immunosuppressive therapy after kidney transplant, who did not respond to the first two doses of COVID-19 vaccine, respond to a third dose. The study, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), aims to determine whether a third dose of either Moderna or Pfizer/BioNTech COVID-19 vaccine could help kidney transplant patients overcome the problem of not developing immune response to the coronavirus even…

Read More